Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
22 March 2023 - 7:01AM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB) today announced that it will report its financial results for
year ended December 31, 2022, on Thursday, March 30, 2023, after
the close of the U.S. financial markets. The announcement will be
followed by a conference call and webcast with the investment
community on Friday, March 31, 2023, at 9:00 a.m. ET. Participating
on the call from Y-mAbs will be Thomas Gad, founder, Chairman and
Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief
Commerical Officer and Vignesh Rajah, Chief Medical Officer.
Conference call and webcast
details:
Investors (domestic): |
|
877-407-0792 |
Investors (international): |
|
201-689-8263 |
Conference ID: |
|
13736579 |
To access a live webcast of the update, please
use this link.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel,
antibody-based therapeutic cancer products. In addition to
conventional antibodies, the Company’s technologies include
bispecific antibodies generated using the Y-BiClone platform and
the SADA platform. The Company’s broad and advanced product
pipeline includes one FDA-approved product, DANYELZA®
(naxitamab-gqgk), which targets tumors that express GD2, and one
product candidate at the registration-stage, omburtamab, which
targets tumors that express B7-H3.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about: our business model,
including the Company’s plans and strategies, development,
commercialization and product distribution plans, as well as our
efforts to potentially build a global franchise of radiotherapeutic
assets; expectations with respect to our products and product
candidates including the potential of the SADA technology and the
potential benefits thereof; and other statements that are not
historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’
“contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’
“hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’
‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Our product candidates and related
technologies are novel approaches to cancer treatment that present
significant challenges. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various factors, including but not limited to: risks associated
with our financial condition and need for additional capital; the
risks that actual results of our restructuring plan and revised
business plan will not be as expected; risks associated with our
development work; cost and success of our product development
activities and clinical trials; the risks of delay in the timing of
our regulatory submissions or failure to receive approval of our
drug candidates; the risks related to commercializing any approved
pharmaceutical product including the rate and degree of market
acceptance of our product candidates; development of our sales and
marketing capabilities and risks associated with failure to obtain
sufficient reimbursement for our products; the risks related to our
dependence on third parties including for conduct of clinical
testing and product manufacture; our inability to enter into
partnerships; the risks related to government regulation; risks
related to market approval, risks associated with protection of our
intellectual property rights; risks related to employee matters and
managing growth; risks related to our common stock, risks
associated with the COVID-19 pandemic; risks associated with the
conflict between Russia and Ukraine and sanctions related thereto;
including inflation and uncertain global credit and capital
markets; and other risks and uncertainties affecting the Company
including those described in the "Risk Factors" section included in
our Annual Report on Form 10-K for the year ended December 31,
2021, our Quarterly Reports on Firm 10-Q for the quarters ending
March 31, 2022, June 30, 2022 and September 30, 2022, and in our
other SEC filings. Any forward-looking statements contained in this
press release speak only as of the date hereof, and the Company
undertakes no obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered
trademarks of Y-mAbs Therapeutics, Inc.
Contact:
Y-mAbs Therapeutics, Inc.230 Park Avenue, Suite 3350New York, NY
10169USA
+1 646 885 8505E-mail: info@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024